Wall Street JournalStrong Merck cancer drug sales upstage rival Bristol-MyersReuters(Reuters) - Investors betting that Bristol-Myers Squibb will emerge as the leading player in a hot new class of cancer drugs hit the pause button on Tuesday as a rival therapy from Merck & Co showed much higher sales. Bristol shares fell as much as 2.7 ...Merck Jumps, United Therapeutics Drops On Q1 Earnings MRK UTHRInvestor's Business DailyDPP-4 Diabetes Drug Not a CV RiskMedPage TodayMarket Undervalues Merck's PipelineMorningstar.comWall Street Journal (blog) -The Australian -WKRB Newsall 160 news articles »
Strong Merck cancer drug sales upstage rival Bristol
Rating: 4.5
Diposkan Oleh: Unknown
